These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37536495)

  • 1. Tracking adoptive natural killer cells via ultrasound imaging assisted with nanobubbles.
    Jiang Y; Hou X; Zhao X; Jing J; Sun L
    Acta Biomater; 2023 Oct; 169():542-555. PubMed ID: 37536495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vivo Tracking of Cell Viability for Adoptive Natural Killer Cell-Based Immunotherapy by Ratiometric NIR-II Fluorescence Imaging.
    Liao N; Su L; Zheng Y; Zhao B; Wu M; Zhang D; Yang H; Liu X; Song J
    Angew Chem Int Ed Engl; 2021 Sep; 60(38):20888-20896. PubMed ID: 34268865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-Time Tracking of
    Uong TNT; Lee KH; Ahn SJ; Kim KW; Min JJ; Hyun H; Yoon MS
    Front Immunol; 2018; 9():825. PubMed ID: 29770131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
    Hu W; Wang G; Huang D; Sui M; Xu Y
    Front Immunol; 2019; 10():1205. PubMed ID: 31214177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depicting adoptive immunotherapy for prostate cancer in an animal model with magnetic resonance imaging.
    Meier R; Golovko D; Tavri S; Henning TD; Knopp C; Piontek G; Rudelius M; Heinrich P; Wels WS; Daldrup-Link H
    Magn Reson Med; 2011 Mar; 65(3):756-63. PubMed ID: 20928869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer.
    Kennedy PR; Felices M; Miller JS
    Stem Cell Res Ther; 2022 Apr; 13(1):165. PubMed ID: 35414042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
    Matosevic S
    J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
    Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
    Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective.
    Cifaldi L; Locatelli F; Marasco E; Moretta L; Pistoia V
    Trends Mol Med; 2017 Dec; 23(12):1156-1175. PubMed ID: 29133133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multifunctional nanoparticles for genetic engineering and bioimaging of natural killer (NK) cell therapeutics.
    Kim KS; Han JH; Park JH; Kim HK; Choi SH; Kim GR; Song H; An HJ; Han DK; Park W; Park KS
    Biomaterials; 2019 Nov; 221():119418. PubMed ID: 31419655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations.
    Sanchez CE; Dowlati EP; Geiger AE; Chaudhry K; Tovar MA; Bollard CM; Cruz CRY
    Transplant Cell Ther; 2021 Jan; 27(1):21-35. PubMed ID: 33007496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET Imaging of the Natural Killer Cell Activation Receptor NKp30.
    Shaffer TM; Aalipour A; Schürch CM; Gambhir SS
    J Nucl Med; 2020 Sep; 61(9):1348-1354. PubMed ID: 32532927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of natural killer cell immunotherapy using noninvasive imaging modalities.
    Jha P; Golovko D; Bains S; Hostetter D; Meier R; Wendland MF; Daldrup-Link HE
    Cancer Res; 2010 Aug; 70(15):6109-13. PubMed ID: 20631071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.
    Suck G; Odendahl M; Nowakowska P; Seidl C; Wels WS; Klingemann HG; Tonn T
    Cancer Immunol Immunother; 2016 Apr; 65(4):485-92. PubMed ID: 26559813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting natural killer cells in cancer immunotherapy.
    Guillerey C; Huntington ND; Smyth MJ
    Nat Immunol; 2016 Aug; 17(9):1025-36. PubMed ID: 27540992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells.
    Ferreira-Teixeira M; Paiva-Oliveira D; Parada B; Alves V; Sousa V; Chijioke O; Münz C; Reis F; Rodrigues-Santos P; Gomes C
    BMC Med; 2016 Oct; 14(1):163. PubMed ID: 27769244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
    Rafei H; Daher M; Rezvani K
    Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gold-seaurchin based immunomodulator enabling photothermal intervention and αCD16 transfection to boost NK cell adoptive immunotherapy.
    Lin X; Li F; Gu Q; Wang X; Zheng Y; Li J; Guan J; Yao C; Liu X
    Acta Biomater; 2022 Jul; 146():406-420. PubMed ID: 35470078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92.
    Tonn T; Becker S; Esser R; Schwabe D; Seifried E
    J Hematother Stem Cell Res; 2001 Aug; 10(4):535-44. PubMed ID: 11522236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural killer cell lines in tumor immunotherapy.
    Cheng M; Zhang J; Jiang W; Chen Y; Tian Z
    Front Med; 2012 Mar; 6(1):56-66. PubMed ID: 22460449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.